ZYME Zymeworks Inc.
8-K Current Report
Filed: March 2, 2026
Health Care
Pharmaceutical PreparationsZymeworks Inc. (ZYME) 8-K current report filed with SEC EDGAR on March 2, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items3 items
- Item 1.01: Entry into a Material Definitive Agreement
- Item 2.03: Creation of a Direct Financial Obligation
- Item 7.01: Regulation FD Disclosure
AI Filing Analysis8-K
Item 1.01 · Entry into a Material Definitive Agreement
- • $250M upfront from Royalty Pharma via royalty monetization of Ziihera (zanidatamab), structured as a royalty sale + non-recourse term loan at subsidiary level
- • Total repayment obligation: ~$481.3M by Dec 31, 2042 maturity; early repayment by Dec 31, 2033 reduces obligation to $412.5M — implying ~65–93% effective cost of capital
Item 2.03 · Creation of a Direct Financial Obligation
- • Item 2.03 covers material financial obligations — key details (amount, rate, maturity, purpose) would determine investor impact
- • Filing text cut off before disclosing any substantive terms of the off-balance sheet arrangement
Item 7.01 · Regulation FD Disclosure
- • Standard Reg FD safe harbor language only — no financial data, operational updates, or material information disclosed in this excerpt
Other Zymeworks Inc. 8-K Filings
Get deeper insights on Zymeworks Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.